Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease

References

• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Disease. Hepatology. 2018;67:328–357.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease- Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.
   PubMed Web of Science ®Google Scholar
• Argo CK, Caldwell SH. Epidemiology and natural history of nonalcoholic steatohepatitis. Clin Liver Dis. 2009;13:511–531.
   PubMed Web of Science ®Google Scholar
• Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62:S47–S64.
   PubMed Web of Science ®Google Scholar
• VanWagner LB, Rinella ME. Extrahepatic manifestations of nonalcoholic fatty liver disease. Curr Hepatology Rep. 2016;15:75–85.
   PubMedGoogle Scholar
• Rockstroh JK. Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in HIV. Curr HIV/AIDS Rep. 2017;14:47–53.
   PubMed Web of Science ®Google Scholar
• Serrano-Villar S, Gutiérrez F, Miralles C, et al. Human immunedeficiency virus as a chronic disease: evaluation and management of nonacquired immune deficiency syndrome-defining conditions. Open Forum Infect Dis. 2016;3:ofw097.
   PubMed Web of Science ®Google Scholar
• Macias J, Rivero-Juarez A, Neukam K, et al. HEPAVIR Study Group. Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals. AIDS. 2015;29:1927–1935.
   PubMed Web of Science ®Google Scholar
• Vuille-Lessard É, Lebouché B, Lennox L, et al. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients. AIDS. 2016;30:2635–2643.
   PubMed Web of Science ®Google Scholar
• Macías J, Real LM, Rivero-Juárez A, et al. Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients. HIV Med. 2016;17:766–773.
   PubMed Web of Science ®Google Scholar
• Vodkin I, Valasek MA, Bettencourt R, et al. Clinical, biochemical, and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study. Aliment Pharmacol Ther. 2015;41:368–378.
   PubMed Web of Science ®Google Scholar
• Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36:1825–1835.
   PubMed Web of Science ®Google Scholar
• Paul J, Venugopal RV, Peter L, et al. Measurement of controlled attenuation parameter: a surrogate marker of hepatic steatosis in patients of nonalcoholic fatty liver disease on lifestyle modification – a prospective follow-up study. Arq Gastroenterol. 2018;55:7–13.
   PubMedGoogle Scholar
• Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–1325.
   PubMed Web of Science ®Google Scholar
• Wai-Sun Wong V, Vergniol J, Lai-Hung Wong G, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51:454–462.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419.
   PubMed Web of Science ®Google Scholar
• Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA Modeling. Diabetes Care. 2004;27:1487–1495.
   PubMed Web of Science ®Google Scholar
• IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definitition. Lancet. 2005;366:1059–1062.
   PubMed Web of Science ®Google Scholar
• Maurice JB, Patel A, Scott AJ, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection. AIDS. 2017;31:1621–1632.
   PubMed Web of Science ®Google Scholar
• Perazzo H, Cardoso SW, Yanavich C, et al. Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono-infection under long-term combined antiretroviral therapy. J Intern Aids Soc. 2018;21:e25201.
   PubMed Web of Science ®Google Scholar
• Price JC, Seaberg EC, Latanich R, et al. Risk factors for fatty liver in the Multicenter AIDS Cohort Study. Am J Gastroenterol. 2014;109:695–704.
   PubMed Web of Science ®Google Scholar
• McGovern BH, Ditelberg JS, Taylor LE, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis. 2006;43:365–372.
   PubMed Web of Science ®Google Scholar
• Blas-Garcia A, Apostolova N, Ballesteros D, et al. Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology. 2010;52:115–125.
   PubMed Web of Science ®Google Scholar
• Carper MJ, Cade WT, Cam M, et al. HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus. Am J Physiol Endocrinol Metab. 2008;294:E558–E567.
   PubMed Web of Science ®Google Scholar
• Sulyok M, Makara M, Rupnik Z, et al. Hepatic steatosis in individuals living with HIV measured by controlled attenuation parameter: a cross-sectional study. Eur J Gastroenterol Hepatol. 2015;27:679–685.
   PubMed Web of Science ®Google Scholar
• Pembroke T, Deschenes M, Lebouché B, et al. Hepatic steatosis progresses faster in HIV monoinfected than HIV-HCV-coinfected patients and is associated with liver fibrosis. J Hepatol. 2017;67:801–808.
   PubMed Web of Science ®Google Scholar
• European AIDS Clinical Society (EACS) Guidelines. Version 9.1, October 2018. Available at: http://www.eacsociety.org/files/2018_guidelines-9.1-english.pdf.
   Google Scholar
• Matthews L, Kleiner DE, Chairez C, et al. Pioglitazone for hepatic steatosis in HIV/Hepatitis C Virus Coinfection . AIDS Res Hum Retroviruses. 2015;31:961–966.
   PubMed Web of Science ®Google Scholar
• Kamari VE, Hileman CO, Gholam PM, et al. Statin therapy does not reduce liver fat scores in patients receiving antiretroviral therapy for HIV infection. Clin Gastroenterol Hepatol. 2019;17:536–542.
   PubMed Web of Science ®Google Scholar
• Calza L, Magistrelli E, Colangeli V, et al. Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study). Infect Dis (Lond). 2017;49:737–747.
   PubMed Web of Science ®Google Scholar
• Macias J, Mancebo M, Merino D, et al. Changes in liver steatosis after switching from efavirenz to raltegravir among human immunodeficiency virus-infected patients with nonalcoholic fatty liver disease. Clin Infect Dis. 2017;65:1012–1019.
   PubMed Web of Science ®Google Scholar
• Curran A, Martinez E, Saumoy M, et al. Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. AIDS. 2012;26:475–481.
   PubMed Web of Science ®Google Scholar
• Martínez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS. 2010;24:1697–1707.
   PubMed Web of Science ®Google Scholar
• Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375:396–407.
   PubMed Web of Science ®Google Scholar
• Randell P, Jackson A, Milinkovic A, et al. An open-label, randomized study of the impact on insulin sensitivity, lipid profile and vascular inflammation by treatment with lopinavir/ritonavir or raltegravir in HIV-negative male volunteers. Antivir Ther (Lond). 2017;22:145–151.
   PubMed Web of Science ®Google Scholar
• Offor O, Utay N, Reynoso D, et al. Adiponectin and the steatosis marker Chi3L1 decrease following switch to raltegravir compared to continued PI/NNRTI-based antiretroviral therapy. PLoS One. 2018;13:e0196395.
   PubMed Web of Science ®Google Scholar